Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity

Conditions: Hypertension and chronic kidney disease

Registration Number: EUCTR2007-005401-22-NL

Lead Sponsor: niversity Medical Center Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: 20

Inclusion Criteria

Patients with stable CKD and hypertension: i.e. using antihypertensive drugs and/or blood pressure >145/90mmHg when off medication.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Patients on renal replacement therapy
-Diabetes mellitus
-Pregnancy

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The primary objective is to investigate the effect on MSNA by Aliskiren in hypertensive patients with CKD. We hypothesize that there will be a (substantial) decrease in MSNA as result of chronic treatment (6 weeks) of Aliskiren. ;Secondary Objective: Secondary objective is to assess whether MSNA normalizes after chronic treatment (6 weeks) of Aliskiren in hypertensive patients with CKD. <br>Furthermore, we will study the effect of Aliskiren on blood pressure, heart rate, kidney function and PRA in hypertensive patients with CKD.<br>;Primary end point(s): Primary endpoint: the effect of Aliskiren on MSNA<br><br>Secondary parameters: Effect of aliskiren on blood pressure, heart rate, PRA and kidney function <br>- Comparison of the effect on MSNA after treatment with aliskiren with the effects on ACEi and ARB as comared to the previous studies and assessment whether normalization of MSNA is obtained after treatment with aliskiren <br>

Secondary Outcome Measures